MDACC Study No:2012-1007 ( NCT No: NCT01722487)
Title:A Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 versus Chlorambucil in Patients 65 Years or Older with Treatment-naive Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Principal Investigator:Jan A. Burger
Treatment Agent:Chlorambucil; PCI-32765
Study Status:Terminated
Study Description:The goal of this clinical research study is to compare the level of
effectiveness of PCI-32765 (ibrutinib) to that of chlorambucil when given to
patients with CLL or SLL. The safety of these drugs will also be compared.

Ibrutinib is designed to stop a protein from working in the cells, which may
cause the cancer cells to die or stop growing.

Chlorambucil is designed to lower the body's harmful response to immune system
diseases, which may cause cancer cells to die.
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase III
Treatment Agents:Chlorambucil
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Pharmacyclics
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Jan A. Burger
For Clinical Trial Enrollment:713-792-8760
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults